PDCD1 and neoplasm: This study showed for the first time that a dynamic in vitro tumor microenvironment can be utilized to distinguish differences in response between two different ICI therapies, anti-CTLA4 and anti-PD-1, against three different syngeneic mouse lines, MC38, CT26 and B16F10, all well-established models for cancer research [40,41].